| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7820671 | VERTEX PHARMS | Peptidomimetic protease inhibitors |
Feb, 2025
(1 year, 5 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8431615 | VERTEX PHARMS | Dose forms |
May, 2028
(4 years from now) | |
Incivek is owned by Vertex Pharms.
Incivek contains Telaprevir.
Incivek has a total of 2 drug patents out of which 0 drug patents have expired.
Incivek was authorised for market use on 23 May, 2011.
Incivek is available in tablet;oral dosage forms.
Incivek can be used as method of treating chronic hepatitis c.
The generics of Incivek are possible to be released after 30 May, 2028.
Drugs and Companies using TELAPREVIR ingredient
Market Authorisation Date: 23 May, 2011
Treatment: Method of treating chronic hepatitis c
Dosage: TABLET;ORAL
More Information on Dosage
INCIVEK family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic